Creating models of acute myeloid leukemia to understand racial differences in treatment outcomes
Official title: Developing Acute Myeloid Leukemia Models with Diverse Ancestral Origins
Funded at Wake Forest University Health Sciences · NIH-11057667 · Data updated 2026-11-12
This study is looking at how acute myeloid leukemia (AML) affects people from different backgrounds, especially focusing on why some groups, like non-Hispanic black patients, may have worse outcomes, with the goal of finding better and more personalized treatments for everyone with AML.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | March 18, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $159,524 |
| NIH project number | 5R21CA283135-02 |
| Project ID | NIH-11057667 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults diagnosed with acute myeloid leukemia, especially those who identify as non-Hispanic black.
✕Less likely to help
Patients with acute myeloid leukemia who do not fall into the specified racial categories or who are not adults may not benefit from this research.
What this research studies
This research focuses on acute myeloid leukemia (AML), a serious cancer affecting the bone marrow, particularly examining how it impacts patients of different ancestral backgrounds. The study aims to develop preclinical models that reflect the genetic diversity of patients, especially non-Hispanic black individuals, who often face worse outcomes compared to their non-Hispanic white counterparts. By utilizing advanced techniques to create these models, the researchers will investigate how these differences affect treatment responses and the underlying biological mechanisms. This could lead to more effective and personalized treatment strategies for AML patients based on their ancestral origins.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with acute myeloid leukemia, particularly those from diverse racial backgrounds.
How similar studies have gone: Previous research has shown that understanding genetic and ancestral differences can lead to significant advancements in treatment efficacy, suggesting that this approach has the potential for success.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Pardee, Timothy Sebastian — Wake Forest University Health Sciences
- Study coordinator: Pardee, Timothy Sebastian
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.